RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The firm offers magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures. RadNet was founded by Howard G. Berger in 1980 and is headquartered in Los Angeles, CA.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Elective whole-body MRI scans are gaining traction through social media promotion, with companies like Prenuvo marketing them for early cancer and disease detection. - Major medical organizations including the American Cancer Society and American College of Radiology do not recommend these scans for asymptomatic individuals due to insufficient evidence of benefit. - Approximately one in five patients receives a finding requiring follow-up, yet many abnormalities ultimately prove harmless, leading to unnecessary anxiety, testing, and procedures. - Research cited in JAMA found that ovarian cancer screening in asymptomatic women did not improve mortality outcomes while leading to over 1,000 unnecessary surgeries.
- Nanox reported Q1 2026 revenue of $4.3 million, up from $2.8 million in Q1 2025, driven by teleradiology services and consolidation of Nanox Health IT. - A Nanox.ARC system is now in commercial use at RadNet, the largest U.S. outpatient imaging center operator, with discussions underway for expanded deployment. - The company withdrew its 2026 revenue target, citing longer-than-expected timelines between commercial agreements, system deployment, and revenue recognition. - Cash and equivalents stood at $44.2 million as of March 31, 2026, with management flagging substantial doubt about the company's ability to continue as a going concern without additional financing.
- SOFIE Biosciences has dosed the first patient in its FAPI-GO Phase 3 trial evaluating [18F]FAPI-74 PET/CT for detecting metastatic disease in gastroesophageal cancers, marking a significant milestone in FAPI-based diagnostics. - The company launched a second Phase 3 study, FAPI-PRO, in December 2025 to assess [18F]FAPI-74's clinical utility in pancreatic ductal adenocarcinoma patients. - Previous Phase 2 results demonstrated promising efficacy with [18F]FAPI-74 showing 100% positive predictive value for detecting FAP-expressing cells and 94% positive predictive value for GI malignancies. - Both multi-site trials target the Fibroblast Activation Protein (FAP) in cancer-associated fibroblasts, representing a novel approach to cancer imaging through the tumor microenvironment.
- GE HealthCare received FDA Premarket Authorization for Pristina Recon DL, the first mammography technology to combine deep learning with iterative reconstruction for enhanced 3D breast imaging. - A clinical study demonstrated that breast radiologists preferred Pristina Recon DL image quality in 99.1% of reviews compared to previous digital breast tomosynthesis reconstruction methods. - The technology utilizes two sequential deep learning models to minimize artifacts and enhance visualization of clinically relevant information while maintaining patient dose safety. - The system offers significant workflow improvements including zero-click acquisition, 2.3-second processing time, and 99% uptime based on analysis of over 42,000 service requests.
- RadNet Inc. has announced plans to acquire iCAD Inc. for approximately $100 million, uniting two leading companies in AI-powered cancer detection technology with a focus on breast cancer screening. - The acquisition, unanimously approved by both companies' boards, is expected to close by Q3 2025 and aims to accelerate innovation in early cancer detection, improve radiologist workflow, and enhance patient outcomes. - The combined entity will leverage RadNet's scale and clinical leadership with iCAD's AI solutions in breast cancer detection, risk evaluation, and density assessment to create a comprehensive platform for advancing population health initiatives.
